ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Tumor biology, immune infiltration and liver function define seven hepatocellular carcinoma subtypes linked to distinct drivers, survival and drug response

Wu, Ruihong; Gao, Yue; Zhao, Xiaoxi; Guo, Shuang; Zhou, Hanxiao; Zhang, Yakun; Hou, Yaopan; Mei, Lan; Zhi, Hui; Wang, Peng; Li, Xia*; Ning, Shangwei*; Zhang, Yunpeng*吉林大学; 哈尔滨医科大学; 1
Computers in Biology and Medicine2023-12DOI: 10.1016/j.compbiomed.2023.107593
2被引6阅读
引用收藏
分享

摘要

Background & aims: Tumor heterogeneity is jointly determined by the components of the tumor ecosystem (TES) including tumor cells, immune cells, stromal cells, and non-cellular components. We aimed to identify subtypes using TES-related genes and determine subtype specific drivers and treatments for hepatocellular carcinoma (HCC). @@@ Methods: We collected 68 genesets depicting tumor biology, immune infiltration, and liver function, totaling 2831 genes, and collected mRNA profiles and clinical data for over 6000 tumors from 65 datasets in the GEO, TCGA, ICGC, and several other databases. We designed a three-step clustering pipeline to identify subtypes. The microenvironment, genomic alteration, and drug response differences were systematically compared among subtypes. @@@ Results: Seven subtypes (TES-1/2/3/4/5/6/7) were revealed in 159 tumors from the CHCC-HBV cohort. We constructed a single sample classifier using paired genes (sscpgsTES). TES subtypes were significantly associated with multiple clinical variables including etiology, and survival in 14 of 17 cohorts and the meta-cohort. TES-1 had the poorest prognosis and highest proliferation level. Both TES-2 and TES-7 were immune-enriched, however, TES-2 had a significantly worse prognosis, and hypoxic and immunosuppressive microenvironment. TES-4 had activated Wnt pathway, driven by CTNNB1 mutation. Good prognosis TES-6 exhibited the best differentiation. TES-5 and TES-3 were considered as novel subclasses by comparing with ten previous subtyping systems. TES-5 tumors had high AFP but good overall survival, and similar to 45% of them harbored AXIN1 mutation. TES-3 was immune and stromal desert, may be driven by high copy number alteration burden, and had the poorest response to immune checkpoint inhibitor. TES-1 and TES-2 had significantly lower response to transarterial chemoembolization, but they showed significantly higher sensitivity to compound YM-155. @@@ Conclusions: Tumor ecosystem subtypes expand existing HCC subtyping systems, have distinct drivers, prognosis, and treatment vulnerabilities.

学科与关键词

关键词
Hepatocellular carcinomaTumor ecosystemSubtypeSingle sample classifierDrug responseImmune desertImmunotherapy response
相关
加载中…
  • The Association between Immune Subgroups and Gene Modules for the Clinical, Cellular, and Molecular Characteristic of Hepatocellular Carcinoma
    Chen, Wenbiao; Zhu, Peng; Xu, Huixuan; Hou, Xianliang; Guo, Changchun*Journal of Oncology, 2022, 2022: 7253876.
  • Identification and analysis of immune-related subtypes of hepatocellular carcinoma
    Wang, Qimeng; Huang, Jin; Zhang, Huihua; Liu, Huan*; Yu, Min*Experimental Biology and Medicine, 2021, 246(6): 667-677.被引 2
  • Characterization of heterogeneous metabolism in hepatocellular carcinoma identifies new therapeutic target and treatment strategy
    Yang, Jiabin; Zeng, Liangtang; Chen, Ruiwan; Zheng, Shangyou; Zhou, Yu*; Chen, Rufu*Frontiers in Immunology, 2023, 14: 1076587.
查看全部 →

发表信息

论文状态
公开发表
期刊
Computers in Biology and Medicine
发表日期
2023-12
卷期
第 167 卷
页码
107593
DOI
10.1016/j.compbiomed.2023.107593
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [62172131, 32070673, 32070672, 32100528]; STI2030-Major Projects [2021ZD0202400]; Heilongjiang Touyan Innovation Team Program; Outstanding Youth Foundation of Heilongjiang Province of China [YQ2021C026, YQ2022C034]

作者

  • W

    Wu, Ruihong (第一作者)

    harbin med univ · 1 · jilin univ

  • G

    Gao, Yue

    harbin med univ

查看全部 13 位作者收起作者
  • Z

    Zhao, Xiaoxi

    harbin med univ

  • G

    Guo, Shuang

    harbin med univ

  • Z

    Zhou, Hanxiao

    harbin med univ

  • Z

    Zhang, Yakun

    harbin med univ

  • H

    Hou, Yaopan

    harbin med univ

  • M

    Mei, Lan

    harbin med univ

  • Z

    Zhi, Hui

    harbin med univ

  • W

    Wang, Peng

    harbin med univ

  • L

    Li, Xia (通讯)

    harbin med univ

  • N

    Ning, Shangwei (通讯)

    harbin med univ

  • Z

    Zhang, Yunpeng (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417